Compounds > sm 10902
Page last updated: 2024-12-10

sm 10902

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SM 10902: a prostacyclin I1 (PGI1) analog; the methyl ester of SM-10906; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5282140
CHEMBL ID2106962
CHEBI ID32002
SCHEMBL ID636273
MeSH IDM0229820

Synonyms (22)

Synonym
acetic acid, (2-(octahydro-5-hydroxy-4-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl)ethoxy)-, methyl ester, (2r-(2-alpha,3a-alpha,4-alpha(1e,3s*,5s*),5-beta,6a-alpha))-
sm 10902
pimilprost [inn]
(+)-methyl (2-((2r,3as,4r,5r,6as)-octahydro-5-hydroxy-4-((1e,3s,5s)-3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl)ethoxy)acetate
pimilprost
sm-10902
skipron
139403-31-9
D01188
pimilprost (jan/inn)
methyl 2-[2-[(2r,3as,4r,5r,6as)-5-hydroxy-4-[(e,3s,5s)-3-hydroxy-5-methylnon-1-enyl]-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]ethoxy]acetate
unii-o316o1zgeg
o316o1zgeg ,
CHEMBL2106962
SCHEMBL636273
(+)-methyl (2-((2r,3as,4r,5-r,6as)-octahydro-5-hydroxy-4-((1e,3s,5s)-3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl)ethoxy)acetate
pimilprost [jan]
CHEBI:32002
Q27285254
pimilprost (jan)
methyl 2-[2-[(2r,3as,4r,5r,6as)-octahydro-5-hydroxy-4-[(1e,3s,5s)-3-hydroxy-5-methyl-1-nonen-1-yl]-2-pentalenyl]ethoxy]acetate
DTXSID301103361
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alprostadil
[no description available]		2.3920prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
iloprost
Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.		2.3920carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
sm 10906
SM 10906: a prostacyclin I1 (PGI1) analog; structure given in first source		3.0850
ConditionIndicatedRelationship StrengthStudiesTrials
Mast-Cell Sarcoma
A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.		01.9810
Muscle Relaxation
That phase of a muscle twitch during which a muscle returns to a resting position.		01.9810
Blood Clot
[description not available]		01.9910
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		01.9910
Alloxan Diabetes
[description not available]		01.9910